Enrolling
The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV
Learn MoreCompleted
Evaluation of E/C/F/TAF switch followed by ledipasivir-sofosbuvir antiviral HCV therapy in HIV-HCV co-infection
Learn MoreCompleted
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals.
Learn MoreEnrolling
A prospective clinical cohort of HIV and hepatitis C virus co-infected patients
Learn MoreEnrolling
Association of vitamin D insufficiency with non-alcoholic fatty liver disease in HIV mono-infected patients
Learn MoreReporting
Use of non-invasive methods for diagnosis of non-alcoholic steatohepatitis (NASH) in HIV patients and therapeutic use of vitamin E
Learn MoreTerminated
Can metformin prevent the progression of liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance?
Learn MoreTerminated
An observational study of Kaletra®/Celsentri® combination therapy
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
